TABLE 2.

Comparison of Toxicity Data in Patients Who Received [177Lu]Lu-PSMA-617 Within EAP and VISION Trial

Any grade AEGrade ≥ 3 AE
EventVISION (n = 529)EAP (n = 117)PVISION (n = 529)EAP (n = 117)P
Anemia*168 (32%)44 (42%)0.0468 (13%)19 (18%)0.15
Thrombocytopenia†91 (17%)51 (49%)<0.00142 (8%)13 (13%)0.13
Neutropenia‡45 (9%)32 (32%)<0.00118 (3%)3 (3%)0.85
Lymphopenia‡75 (14%)65 (66%)<0.00141 (8%)34 (34%)<0.001
Leukopenia†66 (12%)49 (47%)<0.00113 (2%)5 (5%)0.19
177Lu-PSMA-617 discontinuation due to AE63 (12%)15 (13%)0.7837 (7%)7 (6%)0.69

  • ↵* Data are missing for 12 patients.

  • ↵† Data are missing for 13 patients.

  • ↵‡ Data are missing for 18 patients.

  • AE = adverse event.